应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
09939 开拓药业-B
休市中 08-23 16:08:27
0.930
+0.000
0.00%
最高
0.990
最低
0.910
成交量
18.35万
今开
0.930
昨收
0.930
日振幅
8.60%
总市值
4.16亿
流通市值
4.16亿
总股本
4.47亿
成交额
17.05万
换手率
0.04%
流通股本
4.47亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
同源康医药港交所IPO,最新市值为83.44亿港元;电主角完成7亿元A轮融资丨全球投融资周报08.17-08.23
创业邦 · 09:07
同源康医药港交所IPO,最新市值为83.44亿港元;电主角完成7亿元A轮融资丨全球投融资周报08.17-08.23
瞄准癌症新药研发,行业老将带领湖州企业登陆港交所
浙商杂志 · 08-24 09:13
瞄准癌症新药研发,行业老将带领湖州企业登陆港交所
国家金融监督管理总局有关司局负责人:鼓励清单以国家战略需求为导向,将农林牧渔、新能源、医药、船舶和海洋工程等27个产业中的农业机械、风电光伏、光热发电、医药研发、船舶等重要设备和重大技术装备纳入鼓励清单范围。
美港电讯 · 08-23 20:46
国家金融监督管理总局有关司局负责人:鼓励清单以国家战略需求为导向,将农林牧渔、新能源、医药、船舶和海洋工程等27个产业中的农业机械、风电光伏、光热发电、医药研发、船舶等重要设备和重大技术装备纳入鼓励清单范围。
【港股收评】三大股指集体走弱!航运股、医药股普跌
财华社 · 08-23 16:51
【港股收评】三大股指集体走弱!航运股、医药股普跌
【九芝堂增资至8.6亿】金十数据8月23日讯,天眼查App显示,近日,ST九芝发生工商变更,注册资本由约2.98亿人民币增至约8.
美港电讯 · 08-23 16:34
【九芝堂增资至8.6亿】金十数据8月23日讯,天眼查App显示,近日,ST九芝发生工商变更,注册资本由约2.98亿人民币增至约8.
又一家企业新增订单数超预期,医药CXO行业再次释放积极信号
中国制药网 · 08-23 15:42
又一家企业新增订单数超预期,医药CXO行业再次释放积极信号
片仔癀业绩增长失速:成本向下传导不畅 业务拓展成效平平 | 医药半年报
新浪证券 · 08-23 15:24
片仔癀业绩增长失速:成本向下传导不畅 业务拓展成效平平 | 医药半年报
【A股收评:沪指涨0.20% 西部大开发概念股尾盘爆发】金十数据8月23日讯,今日三大指数小幅低开,全天基本维持窄幅震荡走势。
美港电讯 · 08-23 15:03
【A股收评:沪指涨0.20% 西部大开发概念股尾盘爆发】金十数据8月23日讯,今日三大指数小幅低开,全天基本维持窄幅震荡走势。
亚盛医药也上岸了 | 见智研究
华尔街见闻 · 08-23 13:14
亚盛医药也上岸了 | 见智研究
徳琪医药-B(6996.HK)的内生增长基因,藏在差异化的全球权益创新管线里
格隆汇 · 08-23 13:00
徳琪医药-B(6996.HK)的内生增长基因,藏在差异化的全球权益创新管线里
同源康医药-B:盘中涨超 18% 创新高
和讯网 · 08-23 11:54
同源康医药-B:盘中涨超 18% 创新高
【A股午评:沪指涨0.28% 华为产业链大涨】金十数据8月23日讯,今日三大指数集体低开,小幅探底后震荡反弹。截至午间收盘,沪指涨0.
美港电讯 · 08-23 11:33
【A股午评:沪指涨0.28% 华为产业链大涨】金十数据8月23日讯,今日三大指数集体低开,小幅探底后震荡反弹。截至午间收盘,沪指涨0.
同源康医药-B盘中涨超18%创新高 较招股价已涨90%
新浪港股 · 08-23 11:24
同源康医药-B盘中涨超18%创新高 较招股价已涨90%
港股异动 | 同源康医药-B(02410)涨超18%创新高 较招股价已涨90% 总市值突破80亿港元
智通财经 · 08-23 11:11
港股异动 | 同源康医药-B(02410)涨超18%创新高 较招股价已涨90% 总市值突破80亿港元
亚盛医药-B绩后涨超4% 上半年收入同比增长477%
新浪港股 · 08-23 10:05
亚盛医药-B绩后涨超4% 上半年收入同比增长477%
开拓药业-B(09939)股价上升6.452%,现价港币$0.99
阿斯达克财经 · 08-23 09:49
开拓药业-B(09939)股价上升6.452%,现价港币$0.99
港股异动 | 亚盛医药-B(06855)绩后涨超4% 上半年收入同比增超4.7倍 公司现金流保持稳健充沛
智通财经 · 08-23 09:42
港股异动 | 亚盛医药-B(06855)绩后涨超4% 上半年收入同比增超4.7倍 公司现金流保持稳健充沛
亚盛医药-B(06855)上涨5.39%,报29.35元/股
金融界 · 08-23 09:32
亚盛医药-B(06855)上涨5.39%,报29.35元/股
《业绩》亚盛医药(06855.HK)中期纯利1.63亿人民币 亏转盈
阿斯达克财经 · 08-23 02:55
《业绩》亚盛医药(06855.HK)中期纯利1.63亿人民币 亏转盈
万春医药上涨4.23%,报1.97美元/股
金融界 · 08-23 02:43
万春医药上涨4.23%,报1.97美元/股
加载更多
公司概况
公司名称:
开拓药业-B
所属市场:
SEHK
上市日期:
--
主营业务:
开拓药业有限公司是一家临床阶段新药开发商,专注于研究癌症药物及其他雄激素受体(AR)相关疾病药物。该公司的主要在研药物是普克鲁胺。该药物正在中国进行转移性去势抵抗性前列腺癌(mCRPC)的III期临床试验。该公司处于临床阶段在研药物还包括一种II期小分子在研药物Pyrilutamide、一种II期单克隆抗体在研药物ALK-1、一种I期mTOR抑制剂Detorsertib、以及一种hedgehog信号转导途径抑制剂GT1708F。
发行价格:
--
{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":0.93,"timestamp":1724400507034,"preClose":0.93,"halted":0,"volume":183500,"delay":0,"floatShares":447499600,"shares":447499600,"eps":-2.7092953,"marketStatus":"休市中","marketStatusCode":7,"change":0,"latestTime":"08-23 16:08:27","open":0.93,"high":0.99,"low":0.91,"amount":170540,"amplitude":0.086022,"askPrice":0.93,"askSize":543000,"bidPrice":0.91,"bidSize":119500,"shortable":0,"etf":0,"ttmEps":-2.709295247296571,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724635800000},"adr":0,"listingDate":1590076800000,"adjPreClose":0.93,"openAndCloseTimeList":[[1724376600000,1724385600000],[1724389200000,1724400000000]],"volumeRatio":1.4235841723423899,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939","defaultTab":"news","newsList":[{"id":"2462616082","title":"同源康医药港交所IPO,最新市值为83.44亿港元;电主角完成7亿元A轮融资丨全球投融资周报08.17-08.23","url":"https://stock-news.laohu8.com/highlight/detail?id=2462616082","media":"创业邦","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462616082?lang=zh_cn&edition=full","pubTime":"2024-08-25 09:07","pubTimestamp":1724548020,"startTime":"0","endTime":"0","summary":"从已披露金额事件的融资规模来看,消费最高,融资总规模约为7.00亿元人民币。其中智慧新零售电商购物平台 “电主角” 完成7亿人民币A轮融资。其次是智能制造行业,已披露融资总额为4.80亿元人民币。其中电动垂直起降飞行器研发商 “沃兰特” 完成数亿人民币A轮融资。其中江苏披露18个,广东披露12个,北京披露9个。最新市值最高为“同源康医药”83.44亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MjM5OTAzMjc4MA==&mid=2650754928&idx=2&sn=0694d9e0611699349e27deb0e4d1959a&chksm=bf024ffc345764ee32cbd9e513b89b8337d4959dad4a1ec1d68be8176531f54f108751269702&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["09939","BK1515","BK1574","BK1161"],"gpt_icon":0},{"id":"2461087985","title":"瞄准癌症新药研发,行业老将带领湖州企业登陆港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2461087985","media":"浙商杂志","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461087985?lang=zh_cn&edition=full","pubTime":"2024-08-24 09:13","pubTimestamp":1724462012,"startTime":"0","endTime":"0","summary":"点击上方蓝字每一个有商业梦想的人都会关注我们~同源康医药背后,站着一位行业老将——吴豫生,今年60岁的他,在医药行业已超过24年。浙股又双叒叕传来好消息!8月20日,浙江同源康医药股份有限公司(同源康医药,HK2410)成功登陆港交所主板,发行价为12.1港元/股,截至23日收盘,最新市值为78.43亿港元(折合人民币85.70...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OReZUhglJipJ3iiXhmE4TRtD6JhfPxWB0Npfq8eGFdpzwAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OReZUhglJipJ3iiXhmE4TRtD6JhfPxWB0Npfq8eGFdpzwAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240824A026XI00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240824A026XI00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK1574","09939","BK1515","BK1161"],"gpt_icon":0},{"id":"2461493595","title":"国家金融监督管理总局有关司局负责人:鼓励清单以国家战略需求为导向,将农林牧渔、新能源、医药、船舶和海洋工程等27个产业中的农业机械、风电光伏、光热发电、医药研发、船舶等重要设备和重大技术装备纳入鼓励清单范围。","url":"https://stock-news.laohu8.com/highlight/detail?id=2461493595","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461493595?lang=zh_cn&edition=full","pubTime":"2024-08-23 20:46","pubTimestamp":1724417167,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["159940","000941.SH","09939","BK1574","159875","159938","160640","BK1161","399941","BK1515"],"gpt_icon":0},{"id":"2461155255","title":"【港股收评】三大股指集体走弱!航运股、医药股普跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2461155255","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461155255?lang=zh_cn&edition=full","pubTime":"2024-08-23 16:51","pubTimestamp":1724403098,"startTime":"0","endTime":"0","summary":"8月23日,港股三大指数集体走弱。截至收盘,恒生指数跌0.16%,国企指数跌0.08%,恒生科技指数跌1.13%。","market":"other","thumbnail":"https://images.finet.hk/photoLib/title/202408_1/e095c015-be39-42d5-b162-46b1e57a70ce.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202408_1/e095c015-be39-42d5-b162-46b1e57a70ce.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/66c84d9a53243c46f4c8e73c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["NTES","BK1515","YANG","HSTECH","NIO","HSCEI","BILI","BIDU","BK1574","XPEV","09939","BABA","LI","TCEHY","BK1161"],"gpt_icon":1},{"id":"2461559011","title":"【九芝堂增资至8.6亿】金十数据8月23日讯,天眼查App显示,近日,ST九芝发生工商变更,注册资本由约2.98亿人民币增至约8.","url":"https://stock-news.laohu8.com/highlight/detail?id=2461559011","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461559011?lang=zh_cn&edition=full","pubTime":"2024-08-23 16:34","pubTimestamp":1724402079,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0228659784.USD","LU1242518857.USD","BK0239","LU2348773727.SGD","LU2148510915.USD","BK0196","BK0028","BK1574","SGXZ81163826.USD","BK0201","BK0027","LU2328871848.SGD","BK0210","LU0140636845.USD","LU1146622755.USD","BK0054","LU1781817850.SGD","LU0048580855.USD","LU1064131003.USD","09939","601012","BK1515","000061","LU1580142542.USD","BK0224","BK0175","LU0327786744.USD","LU0181495838.USD","000989","LU1820825898.SGD","BK0185","BK0188","LU2153591404.USD","LU1064130708.USD","LU0312595415.SGD","LU2153592121.USD","BK0016","LU1969619763.USD","LU2242644610.SGD","BK0187","LU1328615791.USD","LU1997245094.SGD","159938","LU1997245177.USD","LU1655091616.SGD","LU0370786039.SGD","LU0572944931.SGD","LU0979878070.USD","LU1242518931.SGD","BK1161"],"gpt_icon":0},{"id":"2461646556","title":"又一家企业新增订单数超预期,医药CXO行业再次释放积极信号","url":"https://stock-news.laohu8.com/highlight/detail?id=2461646556","media":"中国制药网","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461646556?lang=zh_cn&edition=full","pubTime":"2024-08-23 15:42","pubTimestamp":1724398955,"startTime":"0","endTime":"0","summary":"有分析人士指出,随着全球医药市场需求的持续增长、国内医药创新政策的不断优化以及 CXO 企业自身能力的提升,中国CXO行业有望迎来更加稳健的发展。据悉,随着药企半年报的集中披露,不少CXO企业业绩增长出现放缓。如作为CXO行业企业之一的 药明生物 近期半年报数据展现了诸多亮点,也在释放行业积极信号。分析人士表示,2024年上半年我国CXO行业业绩表现分化。展望未来,中国CXO行业有望迎来更加稳健的发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082315510695b733ad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082315510695b733ad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1720050803.USD","09939","LU0516422952.EUR","LU1880383366.USD","02269","LU1688375341.USD","LU0823426480.USD","LU0516423091.SGD","LU0051755006.USD","LU0516422366.SGD","LU0348735423.USD","LU0359201612.USD","LU0052750758.USD","LU0320764599.SGD","LU0327786744.USD","BK1521","BK1574","LU0708995583.HKD","LU2039709279.SGD","LU0348825331.USD","LU0588546209.SGD","BK1610","IE00B0JY6N72.USD","LU0856984785.SGD","SG9999002562.SGD","BK1161","LU0516423174.USD","LU0417516738.SGD","LU0572944931.SGD","LU0823426308.USD","BK1515","LU0326950275.SGD","LU0181495838.USD","LU0359202008.SGD","LU0979878070.USD","BK1141","LU1242518857.USD","LU1242518931.SGD","LU0140636845.USD","LU0039217434.USD","BK1576","SG9999002463.SGD","LU0456827905.SGD","LU0307460666.USD","LU1794554557.SGD","LU0417516902.SGD","BK1589","LU0819121731.USD","LU0456846285.SGD","LU0043850808.USD"],"gpt_icon":1},{"id":"2461361558","title":"片仔癀业绩增长失速:成本向下传导不畅 业务拓展成效平平 | 医药半年报","url":"https://stock-news.laohu8.com/highlight/detail?id=2461361558","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461361558?lang=zh_cn&edition=full","pubTime":"2024-08-23 15:24","pubTimestamp":1724397840,"startTime":"0","endTime":"0","summary":" 近日,片仔癀披露2024年半年度报告。公告显示,公司上半年实现营业收入约为56.51亿元,同比增长12%;归母净利润约为17.22亿元,同比增长11.73%;经营活动产生的现金流量净额为3.81亿元,同比下降72.13%。 结合往期半年报业绩来看,2024年上半年片仔癀营收、归母净利润增速进一步下滑,同比增速均创下自2016年以来的新低。 结合片仔癀近年的业务拓展动向来看,公司虽不断尝试新的赛道,但仍未找到行之有效的增长发动机。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/observe/2024-08-23/doc-inckriep8142868.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2024-08-23/doc-inckriep8142868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0196","159938","BK1574","09939","BK1515","600436","BK0239","BK1161","BK0188","BK0028"],"gpt_icon":0},{"id":"2461537388","title":"【A股收评:沪指涨0.20% 西部大开发概念股尾盘爆发】金十数据8月23日讯,今日三大指数小幅低开,全天基本维持窄幅震荡走势。","url":"https://stock-news.laohu8.com/highlight/detail?id=2461537388","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461537388?lang=zh_cn&edition=full","pubTime":"2024-08-23 15:03","pubTimestamp":1724396602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["000557","BK0026","300024","BK0277","BK0094","BK4170","399001","BK0073","BK0126","BK0061","BK0231","BK1515","BK0214","BK0010","BK0250","BK0256","BK0196","002261","BK0090","000062","BK0201","BK1574","002403","159796","BK0005","000016","159526","BK0224","BK0049","BK1161","399006","300531","BK0130","159938","002941","BK0070","161027","159982","000521","BK0172","BK0089","BK4595","BK0269","002987","399300","BK0188","09939","EBON","BK0012"],"gpt_icon":0},{"id":"2461331165","title":"亚盛医药也上岸了 | 见智研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2461331165","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461331165?lang=zh_cn&edition=full","pubTime":"2024-08-23 13:14","pubTimestamp":1724390065,"startTime":"0","endTime":"0","summary":"离经常性盈利更近了一步。","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/be2dea34-f75a-4c06-a1d0-30632ddd76a6.png","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/be2dea34-f75a-4c06-a1d0-30632ddd76a6.png"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3725397","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3725397","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["09939","BK1515","BK1161","BK1574"],"gpt_icon":0},{"id":"2461538497","title":"徳琪医药-B(6996.HK)的内生增长基因,藏在差异化的全球权益创新管线里","url":"https://stock-news.laohu8.com/highlight/detail?id=2461538497","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461538497?lang=zh_cn&edition=full","pubTime":"2024-08-23 13:00","pubTimestamp":1724389243,"startTime":"0","endTime":"0","summary":"ATG-022的独特之处在于它能够有效地靶向作用于表达极低的Claudin 18.2的肿瘤细胞","market":"hk","thumbnail":"https://img7.gelonghui.com/column/6.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/6.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/950852","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1574","BK1583","BK1161","BK1191","09939","06996","BK1515"],"gpt_icon":0},{"id":"2461533302","title":"同源康医药-B:盘中涨超 18% 创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2461533302","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461533302?lang=zh_cn&edition=full","pubTime":"2024-08-23 11:54","pubTimestamp":1724385285,"startTime":"0","endTime":"0","summary":"【同源康医药-B盘中曾涨超 18%,创上市新高】 同源康医药-B 高见 23.1 港元,较招股价 12.1 港元已涨超 90%。截至发稿,股价上涨 15.27%,报 22.50 港元,成交额 631.619 万港元。 据悉,招股书显示,同源康医药是一家临床阶段的生物制药公司,核心业务模式包括通过内部进行小分子药物和其他相关创新药物种类的发现、开发及商业化,以解决在癌症领域,特别是肺癌领域未满足的需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082312542895b6a12e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082312542895b6a12e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1161","02410","BK1574","09939"],"gpt_icon":0},{"id":"2461819605","title":"【A股午评:沪指涨0.28% 华为产业链大涨】金十数据8月23日讯,今日三大指数集体低开,小幅探底后震荡反弹。截至午间收盘,沪指涨0.","url":"https://stock-news.laohu8.com/highlight/detail?id=2461819605","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461819605?lang=zh_cn&edition=full","pubTime":"2024-08-23 11:33","pubTimestamp":1724384013,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["399006","000016","BK0010","BK0126","EBON","159938","BK0256","399001","BK0073","BK0172","BK0061","159526","BK0094","BK0196","002987","002261","BK0026","BK0090","BK0028","BK0089","BK0129","BK0005","BK0231","BK0250","000521","BK1128","BK4170","399300","002403","300024","000062","09939","BK4595","BK0188","BK0122","159982","BK0185","BK1161","300531","BK0012","BK0137","BK0214","BK0130","BK0049","BK1574","161027","01981","BK0077","BK0070"],"gpt_icon":0},{"id":"2461581983","title":"同源康医药-B盘中涨超18%创新高 较招股价已涨90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461581983","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461581983?lang=zh_cn&edition=full","pubTime":"2024-08-23 11:24","pubTimestamp":1724383488,"startTime":"0","endTime":"0","summary":"同源康医药-B(02410)盘中曾涨超18%,高见23.1港元,创上市新高,较招股价12.1港元已涨超90%。截至发稿,股价上涨15.27%,报22.50港元,成交额631.619万港元。\n 据悉,招股书显示,同源康医药是一家临床阶段的生物制药公司,核心业务模式包括通过内部进行小分子药物和其他相关创新药物种类(如PROTAC)的发现、开发及商业化,以解决在癌症领域,特别是肺癌领域未满足的需求。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-08-23/doc-inckrawq1433181.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-08-23/doc-inckrawq1433181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1574","BK1515","02410","09939","BK1161"],"gpt_icon":0},{"id":"2461589933","title":"港股异动 | 同源康医药-B(02410)涨超18%创新高 较招股价已涨90% 总市值突破80亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2461589933","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461589933?lang=zh_cn&edition=full","pubTime":"2024-08-23 11:11","pubTimestamp":1724382707,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,同源康医药-B涨超18%,高见23.1港元,创上市新高,较招股价12.1港元已涨超90%。截至发稿,涨15.27%,报22.5港元,成交额614.7万港元。据悉,招股书显示,同源康医药是一家临床阶段的生物制药公司,核心业务模式包括通过内部进行小分子药物和其他相关创新药物种类的发现、开发及商业化,以解决在癌症领域,特别是肺癌领域未满足的需求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1169124.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","02410","BK1574","09939","159938","BK1161"],"gpt_icon":0},{"id":"2461622588","title":"亚盛医药-B绩后涨超4% 上半年收入同比增长477%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461622588","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461622588?lang=zh_cn&edition=full","pubTime":"2024-08-23 10:05","pubTimestamp":1724378731,"startTime":"0","endTime":"0","summary":"亚盛医药-B(06855)绩后上涨4.67%,现报29.15港元,成交额1762.19万港元。\n 亚盛医药-B发布2024年中期业绩,上半年公司总收入创新高,并首次实现盈利。报告期内,亚盛医药收入创新高,实现收入人民币8.24亿元,较去年同比增长477%,主要来源于产品销售收入和对外合作授权收入等。公司首次实现扭亏为盈,净利润达人民币1.63亿元。公司现金流持续获得改善,保持稳健充沛。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-08-23/doc-inckqwqp9739763.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-08-23/doc-inckqwqp9739763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1574","06855","09939","BK1515","BK1161"],"gpt_icon":0},{"id":"2461865588","title":"开拓药业-B(09939)股价上升6.452%,现价港币$0.99","url":"https://stock-news.laohu8.com/highlight/detail?id=2461865588","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461865588?lang=zh_cn&edition=full","pubTime":"2024-08-23 09:49","pubTimestamp":1724377740,"startTime":"0","endTime":"0","summary":"[上升股]开拓药业-B(09939) 股价在上午09:50比前收市价上升6.452%,现股价为港币$0.99。至目前为止,今日最高价为$0.99,而最低价为$0.93。总成交量为2.55万股,总成交金额为港币$2.398万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR240823641/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1515","BK1574","BK1161","09939"],"gpt_icon":0},{"id":"2461213307","title":"港股异动 | 亚盛医药-B(06855)绩后涨超4% 上半年收入同比增超4.7倍 公司现金流保持稳健充沛","url":"https://stock-news.laohu8.com/highlight/detail?id=2461213307","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461213307?lang=zh_cn&edition=full","pubTime":"2024-08-23 09:42","pubTimestamp":1724377379,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,亚盛医药-B(06855)绩后涨超4%,截至发稿,涨4.13%,报29港元,成交额956.9万港元。消息面上,亚盛医药-B发布2024年中期业绩,上半年公司总收入创新高,并首次实现盈利。报告期内,亚盛医药收入创新高,实现收入人民币8.24亿元,较去年同比增长477%,主要来源于产品销售收入和对外合作授权收入等。公司首次实现扭亏为盈,净利润达人民币1.63亿元。公司现金流持续获得改善,保持稳健充沛。报告期内,亚盛医药的商业化造血能力逐步增强;耐立克的商业化快速推进,实现销售收入人民币1.13亿元,较去年下半年环比增长120%,较去年上半年同比增长5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1169080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","BK1161","BK1574","09939","BK1515","159938"],"gpt_icon":0},{"id":"2461730784","title":"亚盛医药-B(06855)上涨5.39%,报29.35元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2461730784","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461730784?lang=zh_cn&edition=full","pubTime":"2024-08-23 09:32","pubTimestamp":1724376720,"startTime":"0","endTime":"0","summary":"8月23日,亚盛医药-B盘中上涨5.39%,截至09:32,报29.35元/股,成交393.18万元。亚盛医药集团是一家专注于肿瘤、乙肝及与衰老相关疾病治疗领域的创新药物开发的生物医药企业,拥有自主构建的蛋白-蛋白相互作用靶向药物设计平台,并已建立9个已进入临床开发阶段的1类小分子新药产品管线。截至2024年中报,亚盛医药-B营业总收入8.24亿元、净利润1.63亿元。8月22日,2024财年中报归属股东应占溢利1.63亿人民币,同比增长140.51%,基本每股收益0.56人民币。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/08/23093242638680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["159938","BK1574","06855","BK1515","09939","BK1161"],"gpt_icon":0},{"id":"2461220324","title":"《业绩》亚盛医药(06855.HK)中期纯利1.63亿人民币 亏转盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2461220324","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461220324?lang=zh_cn&edition=full","pubTime":"2024-08-23 02:55","pubTimestamp":1724352900,"startTime":"0","endTime":"0","summary":"亚盛医药-B(06855.HK) 公布6月止六个月中期业绩,收益8.24亿人民币(下同),按年增加4.77倍。录得纯利1.63亿元,相较上年同期亏损4.02亿元,亏转盈;每股盈利56分。不派中期息。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-22 16:25。)过往派息公布日期派息事项派息内容2024/03/27末期业绩无派息2023/08/21中期业绩无派息2023/03/22末期业绩无派息 2022/08/26中期业绩无派息 AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20201214152343890_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20201214152343890_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1374306/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1515","BK1574","09939","06855","159938","BK1161"],"gpt_icon":0},{"id":"2461246603","title":"万春医药上涨4.23%,报1.97美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2461246603","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461246603?lang=zh_cn&edition=full","pubTime":"2024-08-23 02:43","pubTimestamp":1724352215,"startTime":"0","endTime":"0","summary":"8月23日,万春医药(BYSI)盘中上涨4.23%,截至02:43,报1.97美元/股,成交4379.0美元。财务数据显示,截至2023年12月31日,万春医药收入总额175.1万美元,同比增长29.61%;归母净利润-2102.6万美元,同比增长36.82%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/08/23024342634614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK1161","09939","BK1515","159938","BK1574"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":-0.0211},{"period":"1month","weight":-0.0882},{"period":"3month","weight":-0.2734},{"period":"6month","weight":-0.3586},{"period":"1year","weight":-0.7486},{"period":"ytd","weight":-0.4294}],"compareEarnings":[{"period":"1week","weight":0.0104},{"period":"1month","weight":0.0174},{"period":"3month","weight":-0.0536},{"period":"6month","weight":0.053},{"period":"1year","weight":-0.0329},{"period":"ytd","weight":0.0331}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是一家临床阶段新药开发商,专注于研究癌症药物及其他雄激素受体(AR)相关疾病药物。该公司的主要在研药物是普克鲁胺。该药物正在中国进行转移性去势抵抗性前列腺癌(mCRPC)的III期临床试验。该公司处于临床阶段在研药物还包括一种II期小分子在研药物Pyrilutamide、一种II期单克隆抗体在研药物ALK-1、一种I期mTOR抑制剂Detorsertib、以及一种hedgehog信号转导途径抑制剂GT1708F。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.058646},{"month":2,"riseRate":0.75,"avgChangeRate":0.213088},{"month":3,"riseRate":0.25,"avgChangeRate":0.062774},{"month":4,"riseRate":0.75,"avgChangeRate":0.545629},{"month":5,"riseRate":0.5,"avgChangeRate":0.006555},{"month":6,"riseRate":0.2,"avgChangeRate":-0.08997},{"month":7,"riseRate":0.6,"avgChangeRate":0.020249},{"month":8,"riseRate":0.2,"avgChangeRate":-0.055312},{"month":9,"riseRate":0,"avgChangeRate":-0.284122},{"month":10,"riseRate":0.25,"avgChangeRate":-0.084422},{"month":11,"riseRate":0.75,"avgChangeRate":0.089012},{"month":12,"riseRate":0.25,"avgChangeRate":-0.241375}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}